Foghorn Therapeutics Inc.
FHTX · Price history
Price at last available close
$2.05
−$1.47 (-41.76%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Foghorn Therapeutics Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system.
How they make money
Foghorn Therapeutics is a clinical-stage biotechnology company that generates revenue primarily through research and development collaboration agreements. These agreements typically involve upfront payments, research funding, and potential milestone payments or royalties contingent upon the successful development and commercialization of therapeutic candidates targeting the chromatin regulatory system.
Products & services
The company develops small-molecule therapies targeting the chromatin regulatory system to treat serious diseases, primarily cancers, using its proprietary Gene Traffic Control platform.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Pharmaceutical and biotechnology companiesSource
Customer concentration
The company's revenue is highly concentrated, as it relies on a limited number of collaboration partners for the majority of its revenue; for the year ended December 31, 2025, a significant portion of revenue was derived from a single collaboration partner.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party vendors for preclinical research, clinical trial management, and the manufacturing of drug substances and products; specific supplier names are not disclosed.Source
Business relationships & partnerships
- Eli Lilly and Company — A strategic collaboration and license agreement to discover, develop, and commercialize oncology therapeutics targeting specific chromatin regulatory system targets.Source
Competitors
Strengths
Sources
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Total debt increased 81.9% versus the same quarter last year.
Compare the added borrowing with available cash, cash generation and maturities. A percentage increase from a small starting balance can look large without measuring the full debt burden.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
30
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
59
Fair
Financial Strength
45
Business Quality / Moat
73
Management
80
Growth Quality
53
Risk / Durability
28
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
30
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
40/100
Building Historical Record
Model Score 40/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Elevated debt risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for FHTX
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can FHTX maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can FHTX fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is FHTX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for FHTX to reach sustainable profitability?
- •What future growth or profitability would be needed to justify FHTX's current valuation?
Essential Investment Snapshot
Wall Street Score
30
Opportunity Score
30
Market Cap
$121.7M
P/E Ratio
-3.6
EPS
$-0.99
52-Week High
$7.61
52-Week Low
$3.27
Beta
2.86
Analyst Target
$12.00
Shares Outstanding
63.0M
Total Revenue
$36.7M
Total Debt
$43.1M
Dividend
No current dividend
Liquidation Value / Share
$-1.29
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Extreme movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for FHTX
Detected from reported data — verify before acting.Elevated debt risk
Negative shareholder equity • Total debt is at least one year of revenue • Free cash flow is negative
Community Sentiment
0 active · 0 total callsNo personal call yet on FHTX.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary Gene Traffic Control platform.
- +Deep expertise in chromatin regulatory system biology.
Potential downside factors
- −Debt risk (elevated): Negative shareholder equity.
- −Total debt is at least one year of revenue.
- −Free cash flow is negative.
- −History of operating losses and expectation of future losses.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
30
Sep 24, 2026
Change
+0.2
points
Current Score
30
Oct 1, 2026
Category Changes
FHTX increased 0.2 points because overall fundamentals improved.
Projected Score
Projected Score
28
Projected Change
-1.6 points
Preliminary comparable-period financial changes suggest decline of approximately 1.6 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$2.05
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.7M | $30.9M | $22.6M | $34.2M | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $21.0M | $3.3M | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $15.7M | $27.6M | $22.6M | $34.2M | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $79.7M | $85.5M | $94.5M | $109.7M | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $26.4M | $27.6M | $28.4M | $32.4M | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $84.2M | $109.7M | $125.3M | $142.1M | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$62.5M | -$71.0M | -$97.2M | -$90.7M | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$68.5M | -$82.1M | -$102.7M | -$107.9M | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$64.6M | -$74.3M | -$86.6M | -$94.2M | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $4.2M | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$64.6M | -$74.3M | -$86.6M | -$98.4M | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-0.99 | $-1.18 | $-1.58 | $-2.34 | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 70.63M | 62.98M | 54.90M | 41.97M | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 70.63M | 62.98M | 54.90M | 41.97M | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$16.1M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.10
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+81.9%
Cash Change
-6.2%
Margin Change
+192.6 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
What Weakened
- Cash position declined
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, net income margin. Pressure indicators included EPS growth, cash levels, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 112.7%. EPS declined 64.3%. Cash declined 6.2%. Total debt increased 81.9%. Net income margin improved by 192.6 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal
Rumor Mill · FHTX
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial